Most Clicked StoriesMore >


Allergan acquires Akarna

BIO SmartBrief | Sep 23, 2016

Allergan agreed to purchase Akarna Therapeutics for $50 million upfront, adding Akarna's lead development compound, AKN-083, for the treatment of nonalcoholic steatohepatitis, to its portfolio. Under the terms of the deal, Allergan will pay undisclosed regulatory, clinical and commercial milestone fees related to AKN-083. Genetic Engineering & Biotechnology News (09/21)


USDA approves Okanagan's biotech Arctic Fuji apple

BIO SmartBrief | Sep 26, 2016

Genentech to collaborate with BioNTech on cancer vaccines

BIO SmartBrief | Sep 22, 2016

AbbVie partners with BioArctic to develop antibodies for Parkinson's

BIO SmartBrief | Sep 21, 2016

Drugmakers commit to fight against antimicrobial resistance

BIO SmartBrief | Sep 21, 2016

Adaptimmune partners with cancer center for T-cell therapies

BIO SmartBrief | Sep 27, 2016

Amgen's biosimilar of AbbVie's Humira gets FDA approval

BIO SmartBrief | Sep 26, 2016

Eleven Bio buys Viventia

BIO SmartBrief | Sep 26, 2016

Allergan to acquire liver treatment developer for up to $1.7B

BIO SmartBrief | Sep 21, 2016

Facebook founder, wife commit $3B to prevent, cure disease

BIO SmartBrief | Sep 23, 2016


Find BIO SmartBrief Issues by Date:



BIO News More >


Save with UniFirst

BIO SmartBrief | Sep 28, 2016

Partnering is open for the BIO Investor Forum

BIO SmartBrief | Sep 28, 2016

Save on shipping with FedEx®

BIO SmartBrief | Sep 27, 2016

Are you looking for top biotech talent? Or looking for a biotech job?

BIO SmartBrief | Sep 27, 2016

Secure document sharing services optimized for life science

BIO SmartBrief | Sep 26, 2016




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more